Home Medicine Ferritin level is associated with metabolic syndrome and elevated alanine aminotransferase in children and adolescents
Article
Licensed
Unlicensed Requires Authentication

Ferritin level is associated with metabolic syndrome and elevated alanine aminotransferase in children and adolescents

  • Kyung Hee Yi , Jin Soon Hwang , Se Won Lim , Jun Ah Lee , Dong Ho Kim and Jung Sub Lim EMAIL logo
Published/Copyright: July 8, 2016

Abstract

Background:

The aim of the study was to investigate the association among elevated serum ferritin, metabolic syndrome (MetS) and ‘elevated alanine aminotransferase (ALT) levels beyond healthy-range limits’ in children and adolescents.

Methods:

We analyzed data from 4855 subjects (2579 male) aged 10–19 who participated in the Korea National Health and Nutrition Examination Survey (KNHANES) (2007–2012).

Results:

The prevalence of MetS and ‘elevated ALT’ tended to increase with an increase in the serum ferritin quartile (p-value for trend: all <0.05). The odds ratios (ORs) for MetS in serum ferritin quartile-Q4 compared to ferritin quartile-Q1 was 1.59 (1.01, 2.55) in females after adjusting for age, body mass index (BMI), and insulin resistance. The ORs for ‘elevated ALT’ in ferritin quartile-Q4 compared to ferritin quartile-Q1 were 4.45 (2.18, 9.10) in male and 3.10 (1.70, 5.66) in female subjects after adjusting for other covariates.

Conclusions:

The independent association between elevated serum ferritin and MetS (or ‘elevated ALT’) begins in children and adolescents.


Corresponding author: Jung Sub Lim, PhD, MD, Department of Pediatrics, Korea Cancer Center Hospital, 215 Gongneungdong, Nowon-gu, Seoul 139–706, Republic of Korea, Phone: +82-2-970-1224, Fax: +82-2-970-2427

Acknowledgments

We thank Sanghui Kweon from the Division of Health and Nutrition Survey for her technical support in analyzing the data.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375:181–3.10.1016/S0140-6736(09)61794-3Search in Google Scholar

2. Choi KM, Kim SM, Kim YE, Choi DS, Baik SH, et al. International Diabetes Federation. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. Metabolism 2007;56:552–8.10.1016/j.metabol.2006.12.003Search in Google Scholar PubMed

3. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403–14.10.1016/j.jacc.2006.09.032Search in Google Scholar PubMed

4. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10.10.7326/0003-4819-137-1-200207020-00006Search in Google Scholar PubMed

5. Park HK, Hwang JS, Moon JS, Lee JA, Kim DH, et al. Healthy range of serum alanine aminotransferase and its predictive power for cardiovascular risk in children and adolescents. J Pediatr Gastroenterol Nutr 2013;56:686–91.10.1097/MPG.0b013e31828b4e67Search in Google Scholar PubMed

6. Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni C, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23.10.1053/jhep.2003.50161Search in Google Scholar PubMed

7. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341–50.10.1056/NEJMra0912063Search in Google Scholar PubMed

8. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta 2010;1800:760–9.10.1016/j.bbagen.2010.03.011Search in Google Scholar PubMed PubMed Central

9. Abril-Ulloa V, Flores-Mateo G, Solà-Alberich R, Manuel-y-Keenoy B, Arija V. Ferritin levels and risk of metabolic syndrome: meta-analysis of observational studies. BMC Public Health 2014;14:483.10.1186/1471-2458-14-483Search in Google Scholar PubMed PubMed Central

10. Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev 2013;29:308–18.10.1002/dmrr.2394Search in Google Scholar PubMed

11. Zhao Z, Li S, Liu G, Yan F, Ma X, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One 2012;7:e41641.10.1371/journal.pone.0041641Search in Google Scholar PubMed PubMed Central

12. Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism 2012;61:1182–8.10.1016/j.metabol.2012.01.007Search in Google Scholar PubMed

13. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol 2007;46:549–52.10.1016/j.jhep.2007.01.004Search in Google Scholar PubMed

14. Sun L, Franco OH, Hu FB, Cai L, Yu Z, et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly Chinese. J Clin Endocr Metab 2008;93:4690–6.10.1210/jc.2008-1159Search in Google Scholar PubMed

15. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr 2008;51:1–25.10.3345/kjp.2008.51.1.1Search in Google Scholar

16. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003;157:821–7.10.1001/archpedi.157.8.821Search in Google Scholar PubMed

17. Yi KH, Hwang JS, Kim EY, Lee SH, Kim DH, et al. Prevalence of insulin resistance and cardiometabolic risk in Korean children and adolescents: a population-based study. Diabetes Res Clin Pract 2014;103:106–13.10.1016/j.diabres.2013.10.021Search in Google Scholar PubMed

18. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422–8.10.2337/diacare.27.10.2422Search in Google Scholar PubMed

19. Kang HT, Linton JA, Shim JY. Serum ferritin level is associated with the prevalence of metabolic syndrome in Korean adults: the 2007–2008 Korean National Health and Nutrition Examination Survey. Clin Chim Acta 2012;413:636–41.10.1016/j.cca.2011.12.011Search in Google Scholar PubMed

20. Vari IS, Balkau B, Kettaneh A, André P, Tichet J, et al. DESIR Study Group. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007;30:1795–801.10.2337/dc06-2312Search in Google Scholar PubMed

21. Park SK, Ryoo JH, Kim MG, Shin JY. Association of serum ferritin and the development of metabolic syndrome in middle-aged Korean men: a 5-year follow-up study. Diabetes Care 2012;35:2521–6.10.2337/dc12-0543Search in Google Scholar

22. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77–85.10.1002/hep.24706Search in Google Scholar

23. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007;46:700–7.10.1016/j.jhep.2006.09.018Search in Google Scholar

24. Brudevold R, Hole T, Hammerstrøm J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS One 2008;3:e3547.10.1371/journal.pone.0003547Search in Google Scholar

25. Fabbrini E, Magkos F, Mohammed BS, Pietka T. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430–5.10.1073/pnas.0904944106Search in Google Scholar

26. Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 2007;56:792–8.10.1016/j.metabol.2007.01.010Search in Google Scholar

27. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009;205:533–7.10.1016/j.atherosclerosis.2008.12.012Search in Google Scholar

28. Stefan N, Häring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol 2013;9:144–52.10.1038/nrendo.2012.258Search in Google Scholar

29. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010;52:1156–61.10.1002/hep.23789Search in Google Scholar

30. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000;355:2181–2.10.1016/S0140-6736(00)02397-7Search in Google Scholar

31. González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, et al. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006;60:802–9.10.1038/sj.ejcn.1602384Search in Google Scholar PubMed

32. Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009;49:887–900.10.1002/hep.22716Search in Google Scholar PubMed PubMed Central

33. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005;7:1040–52.10.1089/ars.2005.7.1040Search in Google Scholar PubMed

34. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010;7:251–64.10.1038/nrgastro.2010.41Search in Google Scholar PubMed

35. Christides T, Sharp P. Sugars increase non-heme iron bioavailability in human epithelial intestinal and liver cells. PLoS One 2013;8:e83031.10.1371/journal.pone.0083031Search in Google Scholar PubMed PubMed Central

36. Stitt C, Charley PJ, Butt EM, Saltman P. Rapid induction of iron deposition in spleen and liver with an iron-fructose chelate. Proc Soc Exp Biol Med 1962;110:70–1.10.3181/00379727-110-27426Search in Google Scholar PubMed

37. Abid A, Taha O, Nseir W, Farah R, Grosovski M, et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009;51:918–24.10.1016/j.jhep.2009.05.033Search in Google Scholar PubMed

38. Tsuchiya H, Ebata Y, Sakabe T, Hama S, Kogure K, et al. High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism 2013;62:62–9.10.1016/j.metabol.2012.06.008Search in Google Scholar PubMed

39. Hämäläinen P, Saltevo J, Kautiainen H, Mäntyselkä P, Vanhala M. Serum ferritin levels and the development of metabolic syndrome and its components: a 6.5-year follow-up study. Diabetol Metab Syndr 2014;6:114.10.1186/1758-5996-6-114Search in Google Scholar PubMed PubMed Central

40. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007;50:949–56.10.1007/s00125-007-0604-5Search in Google Scholar PubMed

41. Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, et al. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009;15:2132–8.10.3748/wjg.15.2132Search in Google Scholar

42. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54.10.1056/NEJM199902113400607Search in Google Scholar

43. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001;50:2444–50.10.2337/diabetes.50.11.2444Search in Google Scholar

44. Hannan TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006;60:759–63.10.1203/01.pdr.0000246097.73031.27Search in Google Scholar

45. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388–93.10.1542/peds.2006-1212Search in Google Scholar

46. Castiella A, Zapata E, Zubiaurre L, Ma Alustiza J, De Juan MD, et al. Impact of H63D mutations, magnetic resonance and metabolic syndrome among outpatient referrals for elevated serum ferritin in the Basque Country. Ann Hepatol 2015;14:333–9.10.1016/S1665-2681(19)31272-4Search in Google Scholar


Supplemental Material:

The online version of this article (DOI: 10.1515/jpem-2016-0045) offers supplementary material, available to authorized users.


Received: 2016-2-5
Accepted: 2016-5-19
Published Online: 2016-7-8
Published in Print: 2016-12-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Non-alcoholic fatty liver disease in children and adolescents
  4. Original Articles
  5. Serum vascular endothelial cadherin and thrombomodulin are markers of non-alcoholic fatty liver disease in children
  6. Ferritin level is associated with metabolic syndrome and elevated alanine aminotransferase in children and adolescents
  7. Dietary fructose intake in obese children and adolescents: relation to procollagen type III N-terminal peptide (P3NP) and non-alcoholic fatty liver disease
  8. Central diabetes insipidus: clinical profile that suggests organicity in Peruvian children: Lima – Peru 2001–2013
  9. Salivary flow rate, buffer capacity, and urea concentration in adolescents with type 1 diabetes mellitus
  10. Cortisol response to adrenocorticotropin testing in non-classical congenital adrenal hyperplasia (NCCAH)
  11. Efficacy of micellized vs. fat-soluble vitamin D3 supplementation in healthy school children from Northern India
  12. Growth curves for congenital adrenal hyperplasia from a national retrospective cohort
  13. The effects of type 1 diabetes mellitus on cardiac functions in children: evaluation by conventional and tissue Doppler echocardiography
  14. The association between single nucleotide polymorphisms of the Apelin gene and diabetes mellitus in a Chinese population
  15. Case Reports
  16. Successful transition to sulfonylurea therapy in two Iraqi siblings with neonatal diabetes mellitus and iDEND syndrome due to ABCC8 mutation
  17. A case of 46,XX dysgenesis and marked tall stature; the need for caution in interpreting array comparative genomic hybridization (CGH)
  18. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide
  19. Acknowledgment
  20. Acknowledgment
Downloaded on 18.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2016-0045/html
Scroll to top button